5-HT1A receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: Bridging the gap between serotonergic and glutamatergic mechanisms-Reference-Cited by-同舟云学术

5-HT1A receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: Bridging the gap between serotonergic and glutamatergic mechanisms

Published:2011-10 Issue:2 Volume:231 Page:195-198
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

Huot Philippe,Brotchie Jonathan M.

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference51 articles.

1. Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study;Arai;Brain Res.,1996

2. Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats;Ba;Neurochem. Res.,2006

3. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile;Bartoszyk;J. Neural Transm.,2004

4. In vitro uptake of dopamine in serotoninergic nerve terminals: a fluorescence histochemical study on vibratome sections of the rat cerebral cortex;Berger;Adv. Biochem. Psychopharmacol.,1978

5. Dopamine uptake in serotoninergic terminals in vitro: a valuable tool for the histochemical differentiation of catecholaminergic and serotoninergic terminals in rat cerebral structures;Berger;Brain Res.,1978

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats;Neurochemical Research;2018-03-23

2. Serotonergic Approaches in Parkinson’s Disease: Translational Perspectives, an Update;ACS Chemical Neuroscience;2017-05-05

3. The novel 5-HT1A, receptor agonist, NLX-112 reduces L-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements;NEUROPHARMACOLOGY;2016

4. The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque;Neuropharmacology;2015-10

5. Modulation of l-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus;Neuropharmacology;2015-08